Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Recruiting NCT07309107

Deep Learning on Amyloid Positons Emission Tomography

Conditions: Alzheimer Disease

Sex: All
Ages: 18 Years – 99 Years
Enrollment: 40
Sponsor: Central Hospital, Nancy, France

Location: CHRU NANCY Brabois, nuclear medicine department Vandœuvre-lès-Nancy

Summary

Reducing injected dose and/or acquisition time in amyloid PET imaging would improve comfort, radiation safety and cost-effectiveness in diagnosis and follow-up of patients. This study evaluates the impact of a deep learning-based noise reduction algorithm on visual analysis and Centiloid quantification when simulating reduced injected doses of \[18F\]flutemetamol.

Eligibility Criteria

Inclusion Criteria: * Patients with objective cognitive impairment, * Referred to our department for a cerebral \[¹⁸F\]flutemetamol positron emission tomography scan between January 1, 2023 and July 1, 2025, Exclusion Criteria: * Patient have objected to the use of their data.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07309107). StuddyBuddy aggregates publicly available trial information.